SS-31 is an aromatic-cationic tetrapeptide better known by its international name elamipretide (code designations MTP-131, Bendavia) and its historical name, the Szeto-Schiller peptide. The compound belongs to a small class of molecules able to accumulate selectively in the inner mitochondrial membrane independently of membrane potential, and it serves as one of the key tools for studying mitochondrial bioenergetics. This monograph is strictly a scientific reference (research use only) and contains no recommendations for human use.
Discovery and historical background
The peptide emerged as a by-product of a program synthesizing analgesic dermorphin analogues in the laboratories of Hazel Szeto (Weill Cornell) and Peter Schiller. The key 2',6'-dimethyltyrosine (Dmt) residue derives from opioid peptides of the DALDA family. Unexpectedly, this family of short cationic peptides was found to concentrate in mitochondria and to exhibit antioxidant activity unrelated to opioid pharmacology. A foundational 2004 study showed that cell-permeable peptide antioxidants targeted to the inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and ischemia-reperfusion injury [1]. Subsequent work described the SS peptides as a new class of neuroprotective agents that reduce reactive oxygen species (ROS) production in neuronal models [2].
Structure and physicochemistry
SS-31 has the primary structure H-D-Arg-Dmt-Lys-Phe-NH₂, i.e. D-arginine, 2',6'-dimethyl-L-tyrosine, L-lysine, L-phenylalanine amide. The free-base molecular formula is C₃₂H₄₉N₉O₅, with a molecular mass of about 639.8 g/mol. Its hallmark is an alternating aromatic-cationic architecture: two basic residues (D-Arg, Lys) confer a net positive charge of roughly 3+ at physiological pH, while two aromatic residues (Dmt, Phe) provide amphipathicity. The C-terminal amide and the D-configuration of the N-terminal arginine increase resistance to aminopeptidases. Dimethylation of the tyrosine shifts the redox properties of the phenolic ring historically linked to direct radical scavenging. The compound is highly water-soluble in physiological buffers and is usually supplied as the acetate salt.
Molecular mechanism
SS-31 was initially interpreted as a mitochondria-targeted antioxidant, but later data reoriented the mechanistic model toward selective binding to cardiolipin, the unique dimeric phospholipid of the inner mitochondrial membrane. Owing to its cationic charge and aromatic residues, the peptide associates electrostatically and hydrophobically with anionic cardiolipin, concentrating in the membrane several thousand-fold [3]. This binding modulates the cytochrome c-cardiolipin interaction: SS-31 prevents cytochrome c from adopting the peroxidase conformation that would otherwise peroxidize cardiolipin, disrupt electron transfer, and initiate release of pro-apoptotic cytochrome c [4]. By protecting cardiolipin, the peptide stabilizes cristae curvature, supports assembly of respiratory supercomplexes, and restores the efficiency of oxidative phosphorylation [3][4].
Signaling and downstream effects
Preserving cristae integrity and cardiolipin-dependent protein complexes has cascading consequences for bioenergetics. In ischemia models, SS-31 re-energizes damaged mitochondria, accelerating the recovery of ATP synthesis and oxygen consumption after reperfusion [5]. Reduced cardiolipin peroxidation limits ROS generation at the electron-leak sites of complexes I and III, secondarily lowering oxidative damage to lipids and proteins. Membrane stabilization raises the threshold for opening of the mitochondrial permeability transition pore (mPTP), reducing matrix swelling, cytochrome c release, and apoptosis activation [1]. The downstream effects of the peptide are therefore largely a consequence of restored membrane biophysics rather than classical receptor signaling.
Structure-activity relationships
Systematic variation of the tetrapeptide backbone has mapped the contribution of individual residues. A comparative study of mitochondria-targeted tetrapeptides showed that the alternation of cationic and aromatic residues, along with the presence of Dmt, is critical for membrane interaction and functional activity; substitutions that alter charge or aromaticity substantially modulate cardiolipin affinity and the bioenergetic effect [6]. These data reconcile the antioxidant and cardiolipin-binding models, indicating that physical insertion of the peptide into the membrane is the primary determinant of activity.
Proteomic interaction landscape
Quantitative cross-linking mass spectrometry made it possible to describe the protein interaction landscape of SS-31 in mitochondria. The peptide was shown to influence the conformation and mutual arrangement of numerous inner-membrane proteins, including components of the respiratory chain and ATP synthase, reconciling the observed functional effects with a reorganization of protein-lipid assemblies around cardiolipin [7]. This provided a structural-proteomic foundation for the mechanism previously inferred from biochemical and biophysical data.
Preclinical research
The preclinical record spans a broad range of mitochondrial-dysfunction models. In a neurodegenerative context, SS-31 in cellular and transgenic amyloid-β-associated models mitigated mitochondrial fragmentation, restored the balance of fission/fusion genes, reduced H₂O₂ production, and preserved synaptic markers, positioning the compound as a candidate for Alzheimer's disease research [8]. In cardiovascular and renal ischemia-reperfusion models, the peptide preserved cristae ultrastructure and bioenergetics [5]. In vascular pathology, SS-31 attenuated experimental abdominal aortic aneurysm, an effect linked to suppression of mitochondrial stress and crosstalk with endoplasmic reticulum stress [11]. Collectively, the preclinical data outline a tissue-broad cytoprotective profile grounded in restoration of the mitochondrial membrane.
Clinical research (as literature facts)
Elamipretide has been studied in several controlled clinical programs, cited here strictly as facts of the published literature. In patients with heart failure with reduced ejection fraction, an early-phase study (PROGRESS-HF) evaluated the novel mitochondria-targeting peptide and its tolerability [9]. The largest is the randomized, double-blind, placebo-controlled phase 3 trial MMPOWER-3 in individuals with primary mitochondrial myopathy: despite acceptable tolerability, subcutaneous elamipretide did not meet its primary endpoints (the 6-minute walk test and a fatigue scale) versus placebo [10]. These results illustrate both the compound's safety profile and the difficulty of translating mitochondrial mechanisms into clinical efficacy. The regulatory pathway of elamipretide in the rare cardiolipin-associated Barth syndrome drew separate attention in 2025 as an example of a first mitochondria-targeting drug.
Pharmacokinetics and metabolism
In clinical studies, elamipretide was administered parenterally (mainly subcutaneously and intravenously), since its peptidic nature precludes enteral bioavailability. The compound is rapidly absorbed, reaching peak plasma concentrations within about one to two hours, with a relatively short half-life on the order of two hours. The D-configuration of the N-terminal arginine and C-terminal amidation slow proteolytic degradation relative to unmodified peptides. Metabolism does not depend substantially on the cytochrome P450 system, lowering the risk of metabolic drug interactions; elimination is predominantly renal. These parameters make the compound a convenient tool for controlled pharmacological experiments [12].
Related compounds and analogues
SS-31 belongs to the Szeto-Schiller peptide family. Related members include SS-02 (Dmt-D-Arg-Phe-Lys-NH₂), which, despite antioxidant activity, differs in charge distribution, and SS-20 (Phe-D-Arg-Phe-Lys-NH₂), which lacks Dmt and shows mitoprotection without a direct phenolic antioxidant motif. This is an important argument for a membrane-centered mechanism. The broader class of mitochondria-targeted tetrapeptides has been examined systematically in structure-activity studies [6]. Historical synonyms for elamipretide include MTP-131 and Bendavia.
Analytical characterization
The identity and purity of SS-31 are confirmed by orthogonal methods. Reversed-phase HPLC (RP-HPLC, high-performance liquid chromatography) with UV detection (absorbance of the Dmt/Phe aromatic residues near ~275 nm) is used to assess purity, which for research-grade material typically exceeds 98%. Electrospray ionization mass spectrometry, or MS (ESI-MS) confirms the molecular mass via the [M+H]⁺ signal near m/z 640 for the free base. Tandem MS/MS sequencing and amino acid analysis verify the sequence, while the counterion (acetate) content is determined separately. For scientifically sound interpretation, the starting material should be characterized before use in model systems.
Handling, reconstitution chemistry, and storage
SS-31 is supplied as a lyophilized powder (usually the acetate salt), hygroscopic and moisture-sensitive. The lyophilizate is stored at −20 °C in a sealed, light-protected container. Reconstitution uses sterile water or aqueous buffers, in which the peptide is highly soluble owing to its cationic residues; concentrated stock solutions are aliquoted to avoid repeated freeze-thaw cycles. In solution, short peptides are prone to slow oxidative and hydrolytic degradation, so working solutions are prepared immediately before an experiment. All operations are performed under good laboratory practice (RUO).
Research applications and model systems
Because of its well-defined molecular mechanism, SS-31 is widely used as a pharmacological probe to test the causal role of cardiolipin and cristae integrity in cell physiology: from isolated mitochondria and cardiomyocyte or neuronal cultures to models of ischemia-reperfusion, aging, and neurodegeneration. The compound serves as a positive control in mitoprotectant screens and as a means of distinguishing membrane-centered effects from classical radical scavenging. Contemporary reviews systematize the structure, mechanism, and research potential of elamipretide, outlining both established facts and open questions of translation [12]. The content of this monograph is intended solely for scientific and educational use.